Epstein ± Barr virus is associated with a number of human proliferative and malignant diseases. It is capable of immortalizing human primary B-lymphocytes in vitro. Studies indicate that latent membrane protein LMP1 is one of the viral proteins essential for this process. In this report, LMP1 was shown to prevent primary mouse embryonic ®broblasts from entering into replicative senescence in vitro. It further suppresses the senescence-associated induction of p16 INK4a , commonly believed to be a key regulator of replicative senescence. In addition, LMP1 was shown to prevent premature senescence provoked by oncogenic ras in mouse embryonic ®broblasts, and to inhibit the oncogene rasmediated induction of p16
Introduction
Epstein ± Barr virus (EBV) is a gamma herpesvirus widespread in all human populations (Henle et al., 1969) and it was the ®rst human tumor virus identi®ed (Epstein et al., 1964) . In addition to being the etiological agent for a variety of lymphoproliferative diseases including infectious mononucleosis, X-linked lymphoproliferative syndrome (Purtilo et al., 1975) , and oral hairy leukoplakia in AIDS patients (Greenspan et al., 1985) , EBV is frequently implicated in human cancers including Burkitt's lymphoma (Magrath, 1990 ), Hodgkin's lymphoma (Jarrett et al., 1991) , and nasopharyngeal carcinoma (NPC; Zur Hausen and Schulte-Holthausen, 1970) . In NPC, EBV is not only always associated with the cancer, but is also present as a homogeneous episomal population that re¯ects clonal expansions of single EBV-infected progenitor cells (Raab-Traub and Flynn, 1986) , leaving little doubt on the pivotal roles of EBV in the development of this cancer.
In vitro, EBV is well known for its ability to override the normal cell growth control mechanism of human B lymphocytes. It induces a continuous proliferation of infected B-cells, resulting in the outgrowth of immortal lymphoblastoid cell lines (LCLs) (for review, Kie, 1996) . This EBV-mediated B-cell immortalization process requires a number of EBV genes encoding latent membrane protein 1 (LMP1) and nuclear antigens EBNA 2, EBNA 3A, EBNA 3C and EBNA LP (Kaye et al., 1993; Cohen et al., 1989; Tomkinson et al., 1993; Mannick et al., 1991) . LMP1 has been a major focus of interest since it was the ®rst EBV gene shown to induce the transformation of certain established rodent ®broblast cell lines (Wang et al., 1985; Baichwal and Sugden, 1989; Moorthy and Thorley-Lawson, 1993) . Perhaps more importantly, among all EBV genes necessary for B-cell immortalization, LMP1 is the only one consistently expressed in many EBV-associated cancers such as nasopharyngeal carcinoma and Hodgkin's lymphoma in immunocompetent patients (Rickinson and Kie, 1996) . Previous studies revealed several functional domains of the cytoplasmic tail of LMP1 that interact with TNF receptor-associated factors (TRAF; Mosialos et al., 1995) and TNF receptor-associated death domain protein (TRADD; , resulting in the activation of transcription factors NFkB (Huen et al., 1995; Mitchell and Sugden, 1995) and AP-1 (Kieser et al., 1997; Eliopoulos and Young, 1998) . Recently, LMP1 was also shown to interact with JAK3 kinase to activate STAT proteins (Gires et al., 1999) . Although studies suggest that mutants at TRAF or TRADD binding domains of LMP1 are at least partially defective for EBV-mediated B-cell immortalization , the roles of the uncovered LMP1 signaling pathways in LMP1-mediated B-cell proliferation and ®broblast transformation are not yet clear.
It is well accepted that normal mammalian ®broblast cells do not divide inde®nitely in vitro. After a limited number of population doublings, they often reach a stable and permanent growth arrest known as programmed replicative senescence (Hay¯ick and Moorhead, 1961; Goldstein, 1990; Campisi, 1996 Campisi, , 1997 . Senescent cells usually exhibit a unique pattern of gene expression. They display characteristic phenotypic markers including the senescence-associated bgalactosidase (SA-b-Gal) activity (Dimri et al., 1995) . After withdrawing from cell cycle despite the presence of serum, the senescent cells remain viable inde®nitely and develop a distinctive morphology: the cells adopt a ¯at and enlarged shape, and display a refractile cytoplasm with thin and long projections (Stein and Dulic, 1995) . It is believed that senescence is a manifestation of an aging process or it may represent a mechanism that protects cells against tumor formation (Goldstein, 1990; McCormick and Wittinghofer, 1996) . Allowing the cells to escape from senescence is thought to be an integral step in the cellular progression toward immortalization and malignant transformation (Goldstein, 1990) .
While the molecular mechanism of cell senescence is still under investigation, a number of genes including p53 tumor suppressor and cyclin-dependent kinase (CDK) inhibitors, p21 WAF1 and p16
INK4a
, were identi®ed as good candidates. The increased expressions of p53, p21, and p16 are detected in human cells which have undergone senescence (Kulju and Lehman, 1995; Alcorta et al., 1996) . Mouse embryonic ®broblast (MEF) cells made from mouse defective for p16 showed a constant and rapid growth rate for up to 50 passages without detectable senescence (Serrano et al., 1996) . Primary human cells de®cient in p21 have increased proliferation capacity in vitro (Brown et al., 1997) . Consistent with this notion, introduction of p53 or p16 gene to respectively defective tumor cells can directly induce replicative senescence (Bond et al., 1996; Uhrbom et al., 1997; McConnell et al., 1998) . All these three proteins are capable of inducing cell cycle arrest, and p53 may achieve it in part by inducing the expression of p21 (El-Deiry et al., 1993) .
In addition to aging, a premature senescence can occur in response to the expression of oncogenic Ras and Raf-1 in a process also mediated through the induction of p53 tumor suppressor, the CDK inhibitors p16 and p21 (Serrano et al., 1997; Zhu et al., 1998) . Further analysis indicates that activated Ras or Raf-1 does not provoke senescence in the ®broblasts de®cient in p53 or p16; instead they cause tumorigenic transformation of these cells (Lin et al., 1998) . It was suggested that senescence might be a dynamic response to an aggressive mitogenic stimulus and therefore provide a safeguard mechanism important for tumor suppression (Serrano et al., 1997; Lin et al., 1998) . Interestingly, both p53 and p16 are mutated at high frequencies in most human cancers, implying that the losses of their functions may have central roles in cancer development.
We recently observed for the ®rst time that LMP1, as a single EBV gene, is sucient to induce the proliferation of primary mouse ®broblasts (Yang et al., 2000) . In this study, we examine the roles and mechanisms of LMP1 in inducing the proliferation of primary cells. We provide here the ®rst evidence that LMP1 eectively prevents the replicative senescence of primary ®broblasts and inhibits the premature cell senescence induced by ras oncogene in association with the suppression of p16 expression.
Results

LMP1 circumvents replicative senescence of primary mouse embryonic fibroblasts
Our previous work suggested that LMP1 induced the proliferation of MEF cells (Yang et al., 2000) . Since it is well known that primary ®broblasts have very limited doubling numbers and they normally undergo replicative senescence after several passages, we ask if LMP1 can circumvent this senescence process. For this purpose, amphotropic viruses containing vector (LNSX) or LMP1 (LNSX ± LMP1) were infected into MEF cells at passage 3. Routinely, more than 50% of the MEF cells were infected (Yang et al., 2000) , and they were passaged weekly without drug selection. At the end of passage 3, the cells containing LMP1 and vector behaved in a similar manner (Figure 1a ). Both cultures continuously proliferated for the next three passages after which the cells with vector started to exhibit signi®cant dierences both in morphology and in proliferative capacity. By passage 7 (11 population doublings), most of the MEF-LNSX cells displayed a refractile cytoplasm with thin and long projections, and they became¯at and enlarged ( Figure 1a ) with apparent growth arrest or cellular senescence (Hay¯ick and Moorhead, 1961) . The cells with LMP1, however, exhibited a higher plating eciency and more vigorous growth than the cells with vector. They were homogeneous of small size with a long spindle shape at passage 7 (Figure 1a ). These cells containing LMP1 were passaged continuously 45 times (70 doublings) without displaying any signi®cant replicative senescence, and therefore, they can be regarded as immortalized cells.
To further con®rm the phenotype of replicative senescence, the activity of endogenous SA-b-Gal, a speci®c biomarker of senescence, was examined. The results showed that the MEF cells containing LNSX displayed a dramatic increase in the percentage of SAb-Gal-positive cells at passage 7 (Figure 1b) . In contrast, the cells with LMP1 showed much fewer SA-b-Gal-positive cells at the same passage and they were also much smaller than the cells with LNSX, as shown by photos taken at the same ampli®cation (Figure 1a,b) . In addition, the cells with LMP1 grew signi®cantly faster (data not shown).
The expression of LMP1 was detected in MEF-LMP1 cells at passage 5 by immunoblotting with an LMP1-speci®c monoclonal antibody, S12 (Figure 1c) . Two prominent immunoreactive bands of molecular weights of 60 and 43 kDa were present in the lysate made from MEF-LMP cells, identical to the immunoreactive bands from the lysate of EBV-positive B95-8 cells. Both proteins were absent in EBV-negative lymphoblastic leukemia MOLT-4 and MEF-LNSX cells. The 60 kDa protein is the full length LMP1 and the 43 kDa one is a degradation product. These results suggest that the expression of LMP1 in MEF cells is associated with the suppression of naturally occurring senescence of MEF.
To examine the eciency of LMP1-mediated suppression of MEF senescence, MEF cells transduced with LNSX or LMP1 were selected with geneticin at passage 4 in another experiment, and they were passaged further. At passage 8, they were ®xed and stained for SA-b-Gal. About 500 cells were counted for each infected cell culture. The results revealed that 97% of MEF-LNSX were positive for SA-b-Gal assay, whereas only 6% of MEF-LMP1 cells were SA-b-Gal-positive, indicating that the LMP1-mediated suppression of MEF senescence is extremely ecient.
LMP1 suppresses the replicative senescence-associated induction of p16 and p21 in MEF Previous work has established a strong association between the senescence of primary ®broblasts and the expression of p16 in both human and mouse ®broblasts (Alcorta et al., 1996; Zindy et al., 1997) . Since LMP1 also suppresses replicative senescence of MEF, we further explored the eect of LMP1 on the induction of p16 associated with cell senescence. Similar to a previous report (Zindy et al., 1997) , our results showed that p16 was up-regulated at passage 5 (or eight population doublings) while MEF cells were still proliferating, and it remained at this elevated level as cells progressed into senescence at passages 7 and 8 ( Figure 2 ). In comparison, such induction of p16 did not happen in MEF-LMP1 cells at passages 5, 10, and 13 (taken at the same time of passages 5, 7, and 8 for MEF-LNSX due to dierent growth rates). The immunoblotting results indicate that LMP1 suppresses the naturally occurring, passage-dependent induction of p16 in MEF cells, and such suppression of p16 induction proceeds the actual senescence.
In addition to the stable induction of p16, there was a moderate, transient induction of p21 at passage 7 for MEF-LNSX cells, after p16 induction ( Figure 2 ). As in the previous reports (Alcorta et al., 1996; Stein et al., 1999) , this p21 induction was transient and subsided after cells reached complete senescence at passage 8. However, the timing of this transient p21 induction appeared to be slightly dierent from previous ®ndings in human ®broblasts, in which the induction of p21 proceeded that of p16. This transient p21 induction was also less apparent in MEF ± LMP1 cells taken at the same time (passage 10 instead of 7 due to a shorter doubling time).
LMP1 overcomes the premature senescence provoked by exogenous H-Ras61L in MEF cells
Previous studies have revealed that ras oncogene induces premature senescence associated with the induction of p16 and p53 (Serrano et al., 1997) . Mutation in p16 or p53, but not p21, abolishes oncogene ras induced premature senescence of MEF cells (Serrano et al., 1997; Pantoja and Serrano, 1999) . Similarly, the rapid premature cellular senescence can also be induced by the expression of exogenous Raf-1, or MEK1 in primary ®broblasts that are downstream of Ras in a Rasdependent mitogenic pathway (Zhu et al., 1998; Lin et al., 1998) . Since LMP1 aects the passage-dependent induction of p16 in MEF cells, we further explored the roles of LMP1 in regulating premature senescence induced by ras oncogene by using an adenovirus with activated H-ras61L oncogene (Ad-Ras). Although this Ad-Ras has not been used for this purpose, it has distinct advantages in eciency and reproducibility of infection, therefore facilitating the subsequent analysis of relevant molecular events in primary cells. For the experiment, MEF cells transduced with LNSX or LMP1 were passaged once before they were infected with AdRas at MOI of 20 FFU. Five to seven days later, while the control adenovirus (Ad-Vector) infected cells showed no signi®cant change, the cells infected by AdRas displayed a typical premature replicative senescence (Figure 3a) . More than 95% of the Ad-Ras-infected MEF cells displayed strong SA-b-Gal staining, further con®rming the induction of senescence by H-ras61L oncogene (Figure 3a) . In contrast, Ad-Ras-infected MEF-LMP1 cells did not show premature senescence. The morphology of MEF ± LMP1/H-ras61L cells remained unchanged. They were proliferative and negative for SA-b-Gal staining. The expressions of LMP1 and HRas were con®rmed by immunoblotting with speci®c antibodies against either LMP1 or H-Ras (Figure 3b) . Thus, the results indicate that LMP1 suppresses premature senescence provoked by ras oncogene in primary MEF cells.
LMP1 inhibits the induction of p16 INK4a and p21 WAF1 by H-ras61L in MEF cells
To elucidate the molecular mechanism of LMP1 to suppress the cell senescence induced by oncogenic Hras61L in MEF cells, the expressions of several cell cycle regulatory proteins including cyclin A, cdk4, pRb, p16, p53, and p21 proteins were examined. An antibody against b-actin was also used to control loading. The immunoblotting results provided evidence consistent with the cell growth arrest induced by Hras61L. While the level of CDK4 remains unchanged, the level of S phase-speci®c cyclin A is signi®cantly reduced by Ad-Ras (Figure 4 ). In agreement with the results on the ability of LMP1 to suppress ras-induced cell senescence, the presence of LMP1 prevented Hras61L from suppressing the expression of cyclin A.
Our results further reveal that both p16 and p21 were signi®cantly up-regulated as in Ad-Ras-infected MFE-LNSX cells as they displayed premature senescence (Figure 4 ). In addition, p53 was also slightly up-regulated. In contrast, such induction of p16, p21, and p53 by Ad-Ras was absent in MEF ± LMP1 cells. Of note, consistent with the induction of p16 and p21, pRb was present only in the hypophosphorylated form in Ad-Ras-infected MEF ± LNSX cells but not in the others. Thus, the presence of LMP1 inhibits the induction of p16 and p21 by oncogenic H-ras61L, correlating with LMP1-mediated suppression of premature cell senescence induced by ras oncogene.
LMP1 inhibits p16 promoter in REF52 and Saos-2 cells
To further explore the mechanism of LMP1 to regulate the expression of p16, promoter transactivation studies were carried out with a p16 promoter Figure 2 LMP1 suppresses the passage-dependent induction of p16 in MEF cells. MEF cells were infected with either LNSX or LMP1 retrovirus and passaged without drug selection. Cell lysates were made at the indicated passage number and 100 mg of each lysate was analysed on immunoblotting with speci®c antibodies reporter plasmid (pGL2-B1214) that contains 71214 to 71 of p16 promoter sequence upstream of a luciferase reporter gene (Hara et al., 1996) . This p16 reporter plasmid was co-transfected into rat embryonic ®broblast REF52 cells with increasing amounts of pLNSX ± LMP1 plasmid. After being normalized against a co-transfected CMV b-Gal plasmid, the relative luciferase activities were plotted and shown in Figure 5 . The results indicated a signi®cant inhibition of p16 promoter by the co-transfecting pLNSX ± LMP1 plasmid (Figure 5a ). Up to 3 ± 4-fold inhibition of the p16 promoter activity was observed. The potency of inhibition is comparable with that of a co-tranfecting plasmid encoding a nonphosphorylatable pRB in a pRB-negative cell line (Hara et al., 1996) .
Since pRB negatively regulates p16, we want to determine if the negative regulation of p16 promoter by LMP1 is dependent on intact pRB function. A pRB-negative cell line Saos-2 was used in the p16 promoter assay. The results revealed that LMP1 down-regulated the p16 promoter in a dosagedependent manner with about twofold inhibition (Figure 5b) , suggesting that the process of inhibiting the p16 promoter by LMP1 may not require a functional pRB.
In contrast to the inhibition of the p16 promoter, LMP1 signi®cantly stimulates a NF-kB promoter reporter in REF52 cells (Figure 5c ), consistent with all previous reports. Furthermore, LMP1 failed to eect p21 WAF1 promoter in a transactivation assay (Figure 5d ), suggesting that LMP1-mediated promoter suppression is speci®c to p16 promoter.
LMP1 prevents oncogene ras-induced senescence of immortalized rat embryonic fibroblast REF52 and human diploid fibroblast IMR90 LMP1 suppresses the senescence while inducing the proliferation of MEF cells. To determine if the state of cell proliferation is important for LMP1 to suppress cellular senescence, we used utilized immortalized The respective cell lysates were made 7 days after the adenovirus infections and analysed for the expression of LMP1 and H-Ras. b-actin was used as loading control REF52 cells that display a high degree of growth control and require the co-expression of cooperative oncogenes for transformation (Franza et al., 1986) . Previous experiments showed that oncogenic H-rasV12 induced premature cell senescence in REF52, which was similar to that of MEF cells (Serrano et al., 1997) . In our experiment, REF52 cells were infected with retroviruses containing LNSX and LMP1, followed by geneticin selection for 2 weeks. The geneticin-resistant cells were pooled together for further analysis. The transduction of LMP1 into REF52 cells had little observable eect on cell morphology, growth rate, or the state of transformation (data not shown). To analyse the eect of LMP1 in preventing ras-induced premature senescence in REF52 cells, both REF52 ± LNSX and REF52 ± LMP1 cells were infected with either Ad-Vector or Ad-Ras at 20 MOI and further incubated for 7 days prior to SA-b-Gal assay. The REF52 ± LMP1/H-ras61L cells continued to proliferate to produce cells that covered the entire plate while the REF52 ± LNSX/Ad-Ras cells stopped dividing and displayed intense SA-b-Gal staining (Figure 6a ), indicating that LMP1 also prevented the senescence induced by Ad-H-ras61L in the immortalized REF52. The expression of LMP1 was con®rmed with immunoblotting (Figure 6b ). The expression result for p16 is not available since our antibodies do not recognize rat p16.
Alternatively, REF52 were transfected with vector plasmid pBabe (with a puromycin-resistant gene), pBabe-H-rasV12 (Serrano et al., 1997) , or co-transfected with both pBabe-H-rasV12 and pLNSX-LMP1 plasmids. Following the transfection, the cells were selected for the presence of H-rasV12 gene with puromycin for 2 weeks. The results after the selection indicated that pBabe-H-rasV12-transfected REF52 cells failed to produce any focus of growth as they were presented with typical senescence, large,¯at, incapable of dividing, and exhibiting a strong blue signal after SA-b-Gal staining (Figure 6c) . However, when pLNSX ± LMP1 plasmid was co-transfected into the cells with pBabe-H-rasV12, a large number of cell clones were visible after 2 weeks and SA-b-Gal activity was absent in the majority of the cells (Figure 6c) . Thus, the ability of LMP1 to suppress H-ras oncogeneinduced senescence was con®rmed with another HrasV12 allele by using a dierent method of gene delivery.
Since EBV is a human oncogenic virus, it is important to demonstrate the ability of LMP1 to suppress ras-induced premature senescence in human cells. As in previous experiments, the presenescent human diploid ®broblasts IMR90 were infected with retroviruses containing LNSX or LMP1. The infected cells were further selected with geneticin. Similar to the case of REF52 cells, there was little noticeable dierence in cell morphology and growth rate between these two populations (data not shown). The IMR90 ± LMP1 cells maintained complete contact inhibition. The geneticin-resistant cells were then pooled and infected with Ad-Ras at 20 MOI. After further incubation for 7 days, the Ad-Ras-infected IMR90 ± LNSX cells were presented with clear morphological features of cell senescence and they were positive for SA-b-Gal staining (Figure 7a ). In contrary, the IMR90 ± LMP1/H-ras61L cells were proliferating and negative for SA-b-Gal. Therefore, the results demonstrate that LMP1 also prevents ras-induced cell senescence in the presenescent human diploid ®bro-blasts. Expression studies further revealed that Ad-Ras failed to induce p16 expression in IMR90 ± LMP1 cells (Figure 7b,c) . Interestingly, the basal level of p16 in IMR90 ± LMP1 was lower than that in IMR90 ± LNSX cells, suggesting that LMP1 may down-regulate the expression of p16 in IMR90 cells.
Discussion
EBV is often associated with human proliferative diseases and cancers. In vitro, EBV is known for inducing the immortalization of resting B-cells and LMP1 is one of the viral genes essential in this process (Kaye et al., 1993) . Other studies suggest that LMP1 may act as a constitutive active receptor molecule . Its continuous presence is necessary to maintain B-cell proliferation and it may mimic an activated CD40 receptor (Kilger et al., 1998) that shares a number of signaling pathways with LMP1, such as NF-kB and JNK. This is further supported by mutation studies of LMP1 in which the two transformation eector sites were mapped to the same sites required for NF-kB activation and one of them required for JNK activation (Kaye et al., 1995; . However, it is yet not known how the activation of NF-kB or JNK by LMP1 leads to the proliferation and immortalization of resting B-cells. While EBV is an important Figure 4 The H-ras61L-dependent induction of p21 and p16 were inhibited by LMP1. Immunoblotting analysis of cell lysates was done the same way as that in Figure 3b with antibodies speci®c to the indicated mouse proteins. b-actin was used for loading control pathogenic agent involved in B-cell diseases, its role in disease development is not restricted to B-cells as it is also frequently implicated in oral hairy leukoplakia in AIDS patients, Hodgkin's lymphoma, and nasopharyngeal carcinoma. Therefore, the eect of EBV in inducing cell proliferation and in tumorigenesis is likely to be common among dierent cell types.
We recently showed that a single LMP1 is capable of inducing a continuous proliferation of primary MEF cells (Yang et al., 2000) . Since the excessive proliferation can be the ®rst step of a long march towards malignancy, we focused on the mechanism of the LMP1-induced primary cell proliferation in this study. Our results indicate that the expression of LMP1 in MEF cells results in a suppression of replicative senescence. The LMP1-mediated suppression of senescence is extremely ecient. After the selection of retroviral infected MEF, the LMP1 positive MEF cells were almost completely free of replicative senescence (6% for MEF-LMP1 versus 97% for the control MEF as indicated by the presence of acidic b-Gal). Since senescence is thought to be a process that primary cells employed to stop proliferating and to irreversibly withdraw from cell cycle (Stein and Dulic, 1995) , we suggest that in addition to stimulating cell growth, that the ability of LMP1 to suppress senescence is also important for LMP1-mediated proliferation and immortalization of MEF cells. This new knowledge may help us to understand the roles of EBV in inducing the proliferation immortalization of resting B-cells, and in the development of other EBV-related human diseases.
Moreover, LMP1 eectively suppresses premature senescence induced by mitogenic H-ras61L in primary mouse MEF, immortalized rat embryonic ®broblasts REF52, and presenescent human lung diploid ®bro-blasts IMR90. While MEF are freshly isolated primary cells, REF52 cells are immortalized rat ®broblasts that display a high degree of growth control and require cooperating oncogenes for transformation. In all three types of cells, the presence of LMP1 eectively prevents premature senescence, indicating that the ability of LMP1 to suppress ras-induced senescence is a common phenomenon. The data suggest that the (c) REF52 cells were transfected with plasmids pBabe, pBabe-H-rasV12, or cotransfected with equal amounts of pBabe-H-rasV12 and pLNSX ± LMP1. The transfected cells were selected with puromycin (for pBabe) for 2 weeks, followed by SA-b-Gal staining. Photos were taken at 1006 magni®cation presence of LMP1 allows the cells to be more tolerant to additional oncogenic mutations that would otherwise lead to cell growth arrest or senescence. Furthermore, our results further reveal that LMP1 prevents the induction of p16 associated with replicative senescence, and the induction of both p16 and p21 associated with premature senescence induced by ras oncogene. Our ras-induced senescence results are consistent with the previous report (Serrano et al., 1997) , notwithstanding the dierences in oncogenic ras alleles (H-ras61L instead of H-rasV12) or gene delivery methods in the two experiments. While much work needs to be done to understand the mechanism of LMP1-mediated suppression of replicative senescence, the suppression of p16 is likely to have an important role in this process. Previous studies have shown that MEF cells without either p16 or p53 would fail to undergo senescence and could be easily established into immortalized cell lines (Harvey et al., 1993; Metz et al., 1995; Serrano et al., 1996) , whereas those from p21 null mice undergo senescence upon continuous culture in vitro and are refractory to transformation by ras oncogene (Pantoja and Serrano, 1999) . Consistent with this notion, when primary MEF cells approach senescence, p21 expression is only transiently elevated (passage 7 in our experiment), indicating that it may not be needed to maintain the senescence. The p16 upregulation, on the other hand, appeared earlier than p21 in the proliferating MEF at passage 5, and persisted throughout the process of senescence. Because LMP1 suppresses the p16 induction that appears to proceed the replicative cellular senescence in MEF cells (Figure 4 ; Zindy et al., 1997) , it is tempting to suggest that the inhibition of p16 expression contributes to, rather than results from the suppression of replicative senescence in MEF. While LMP1 inhibits the expression of senescence-associated induction of p16, this inhibition may be dierent from the loss of p16 gene as ras oncogene transforms MEF from p16
INK4a
/p19
ARF null mice but fails to transform MEF with LMP1 (Serrano et al., 1996; Yang et al, 2000) . Instead, LMP1 cooperated with CDK4 R24C in transforming MEF, possibly because LMP1 may have additional proliferating activity and that CDK4 R24C may also aect the inhibition mediated by other INK4 family members (Roussel, 1999; Yang et al, 2000) .
By using a p16 promoter reporter, we demonstrated that LMP1 exhibited a minimal but speci®cally inhibitory eect on the p16 promoter in both REF52 and Saos-2 cells. In REF52 cells where LMP1 inhibits ras-induced senescence, LMP1 down-regulates p16 promoter by 3 ± 4-fold. It is well established the pRB can also negatively regulate the expression of p16 (Draetta, 1994) . The same p16 promoter was negatively regulated by co-transfecting plasmid encoding a nonphosphorylatable pRB for about 3 ± 4-fold in pRB-negative C-33A cells (Hara et al., 1996) . Neither p53 nor pRB appears to be essential for LMP1 to inhibit p16 expression since Saos-2 is defective for both p53 and pRB. It is not known whether the inhibitory function of LMP1 is related to the previously reported NF-kB or AP-1 transactivation activity (Huen et al., 1995; Mitchell and Sugden, 1995; Kieser et al., 1997; Eliopoulos and Young, 1998) . It is interesting to note that LMP1 mutants with defective transformation eector site 2 is defective in inducing long-term outgrowth of B-cells (Kaye et al., 1995 (Kaye et al., , 1999 , as they have also lost most of the NF-kB and AP-1 transactivation activities. It is possible then to use similar mutants to delineate the functional requirement of LMP1 in suppressing replicative senescence.
The abilities of LMP1 to prevent replicative senescence and premature senescence provoked by oncogenic ras may be important for the oncogenic process mediated by EBV. It is well established that the cancer development process often involves multiple mutations in both oncogenes and tumor suppressor genes. Tumor suppressor gene p53 is mutated in a large number of human cancers since it plays a gatekeeper role against the formation of cancer by eliminating the genetically damaged cells (Levine, 1997) . Similarly, p16 is another important tumor suppressor. Since both p53 and p16 may participate in inducing the senescence of cells expressing mitogenic oncogenes, by suppressing the induction of p16, LMP1 may prevent cell senescence and allow the mutated cells to continue proliferating. Such altered cell cycle checkpoint regulation mediated by LMP1 may have a pivotal role in the development of EBV-associated cancers in both tumor initiation and promotion. It is interesting to point out that the transforming protein Tax of Human T-Cell Leukemia Virus 1 interacts directly with p16 and suppresses its activity (Suzuki et al., 1996; Low et al., 1997) , suggesting that p16 may be a common target for both HTLV-1 and EBV to induce cell proliferation and cancer development.
Such activities of LMP1 may further help us to understand the roles of LMP1 and EBV in the development of EBV-associated cancers, i.e., nasopharyngeal carcinoma. NPC is regarded as the result of clonal expansion of single EBV-infected progenitor cells (Raab-Traub and Flynn, 1986) . In addition, a previous analysis of the rare EBV-associated preinvasive nasopharyngeal lesions revealed that these lesions are also clonal and likely arose from single EBV-infected cells. Therefore, it was suggested that EBV infection is a very early, possibly the initiating, event in the development of this cancer (Pathmanathan et al., 1995) . These pre-invasive lesions were much rarer when compared with NPC in the same sample set (11 against 56) and about half of them progressed into NPC within 1 year, suggesting that the EBV-induced proliferative lesions progress rapidly to cancer (Pathmanathan et al., 1995) . In addition, the examination of the expression of EBV genes revealed that neither latent transactivator EBNA2 nor lytic transactivator ZEBRA is present in these lesions. LMP1 is the only known EBV protein required for B-cell immortalization expressed in all of these pre-invasive lesions (Pathmanathan et al., 1995) . Moreover, p53 mutations are rare (Spruck et al., 1992; Sun et al., 1992) , and point mutations in p16 are also rare in NPC but its expression is often down-regulated (Sun et al., 1995; Gulley et al., 1998) . Based on our results on LMP1 and the pathological ®ndings of this cancer, it is attractive to suggest that LMP1 may have two roles in the development of NPC. First, it may provide the initial proliferating potential; and then, by altering cell cycle checkpoint regulation, it allows the accumulation of mitogenic mutations to enable cancer development at an accelerated rate. The ability of LMP1 to suppress p16 expression may contribute to both processes.
Materials and methods
Cell lines and plasmids
MEF cells were prepared fresh from day 14 mouse embryos of pregnant BALB/c mice. After removing the head and the red organs, the torso was minced followed by digestion with 0.1% trypsin and 0.1% collagenase for 30 min at 378C and plated as passage 1. The MEF cells were maintained by continual passage into fresh media when they became con¯uent (1 : 3 split, equivalent to 1.6 population doubling). The cells were routinely infected with retroviruses containing LMP1, or vector LNSX at passage 3. MEF cells normally proliferate until passages 5 ± 6, after which time they enter into senescence. REF52 cells were kindly provided by Dr Joseph R Nevins. IMR90, 293, PA317 (amphotropic), and Bosc23 (ecotropic) were obtained from American Type Culture Collection. All cells were maintained in Dulbecco's modi®ed Eagle medium (DMEM) supplemented with 10% fetal bovine serum (GIBCO). The retrovirus plasmid pBabe-H-rasV12 was a gift of Dr Scott W Lowe (Serrano et al., 1997) . The p16 promoter reporter plasmid pGL2-p16 (71214 to 71) and the pGL2 were gifts of Dr Gordon Peters (Hara et al., 1996) . The plasmid WWP-Luc (containing 2.4 kb WAF1 promoter) was provided by Dr Bert Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD, USA). The plasmid ELAM-luciferase (NF-kB reporter) was provided by Dr David Goeddel (Tularik, South San Franscisco, CA, USA).
Retrovirus and adenovirus-mediated gene transfer
The retrovirus containing pLNSX ± LMP1 (LMP1) was generated and prepared as described previously (Yang et al., 2000) . All retroviruses were maintained in packaging cells PA317 and, in most cases, used as fresh viral stocks without freezing. The titers were determined and infections were carried out as previously described (Yang et al., 2000) . Adenoviruses with the vector (Ad-Vector) and with Ras (AdRas) containing H-ras61L are gifts of Dr JR Nevins (Farnsworth and Feig, 1991; Leone et al., 1997) . To obtain the adenovirus stocks, the viruses were infected into 293 cells. The cells were then harvested 16 ± 24 h later when cytopathic eect was seen. After freezing and thawing three times in 10 ml of fresh medium, the virus containing supernatants were collected and stored. The virus titers were determined by infecting 293 cells with serial dilutions of the virus stocks. The target cells were infected with Ad-Ras or Ad-Vector at a multiplicity of infection (MOI) of 20 focus forming units (FFU) per cell.
Transfection and selection
About 1610
5 Rat-1 cells were seeded into 6-well plates on the previous day. Transfection was carried out by using FuGene (GIBCO) with 2 mg total plasmid DNA per transfection. Two days after transfection, the cells were split and selected with puromycin (2 mg/ml) for the presence of pBabe-H-rasV12. Foci were observed 2 weeks later and photographed.
Immunoblot analysis
Cells were collected and lysed in NP-40 lysis buer . After determining the protein concentration of the cell lysates with Bradford assay, 100 mg of protein was loaded per lane, separated on 10% or 15% SDS ± PAGE gels and transferred to nitrocellulose membrane by electroblotting. Immunoblotting analysis was carried out according to standard procedures with ECL detection system (Amersham). The following primary antibodies were used: S12 for LMP1 (cell culture supernatant, 1 : 20); F-235 for H-Ras (Santa Cruz, 1 : 250); CM5 for rodent p53 (Novacastra, 1 : 250); F-5 for rodent p21 (Santa Cruz, 1 : 250); M156 for rodent p16 (Santa Cruz, 1 : 250); H156 for human p16 (Santa Cruz, 1 : 250); C-19 for cyclinA (Santa Cruz, 1 : 500); H-303 for CDK4 (Santa Cruz, 1 : 250); and 14001 A for Rb (PharMingen, 1 : 250), respectively. HRP conjugated sheep anti-rabbit or anti-mouse antibodies were used as secondary antibodies.
SA-b-galactosidase assay for senescence
Senescence-associated b-Gal (SA-b-Gal) activity was determined as previously described (Dimri et al., 1995; Serrano et al., 1997) with slight modi®cations. Cells were washed twice with PBS and ®xed with 0.5% glutaraldehyde in PBS for 10 min at room temperature. They were then washed with PBS (pH 6.0) supplemented with 1 mM MgCl 2 . The cells were stained in X-gal solution (0.5 mg/ml X-gal, 0.12 mM K 3 Fe[CN] 6 , 0.12 mM K 4 Fe[CN] 6 , 1 mM MgCl 2 in PBS, pH 6.0) for 8 ± 12 h at 378C.
p16 promoter analysis
The experiment was carried out as described (Hara et al., 1996) . For each transfection, 2610 5 REF52 or Saos-2 cells were co-transfected with 100 ng of p16 promoter reporter, 100 ng of CMV-lacZ, and up to 10 times of pLNSX ± LMP1. Vector pLNSX was added to a total of 2 mg DNA per transfection with FuGene6 (GIBCO). Both luciferase and bGal activities were measured 48 h later. The relative promoter activities were calculated based on the ratio of the luciferase to the b-Gal values. All experiments were performed in triplicate each time and at least three independent experiments were performed for each result.
